Research Topic · Peer-Reviewed

Alpha-adrenergic Antagonist Therapy

Hypertension is a serious medical condition that affects millions of people worldwide. It is often referred to as the "silent killer" due to its insidious nature, and affects over 1 billion people worldwide. One of the most common treatments for hypertension and other cardiac conditions is alpha-adrenergic antagonis…

📚 0 peer-reviewed articles cited 🔖 ISSN 2329-9487 🗓 Reviewed July 2026

Overview

Hypertension is a serious medical condition that affects millions of people worldwide. It is often referred to as the "silent killer" due to its insidious nature, and affects over 1 billion people worldwide. One of the most common treatments for hypertension and other cardiac conditions is alpha-adrenergic antagonist therapy. Alpha-adrenergic antagonists are a class of drugs that block the action of norepinephrine on alpha-1 receptors in the peripheral nervous system. This results in a relaxation of smooth muscle tissue in the walls of blood vessels, leading to a decrease in blood pressure. They are commonly prescribed to treat hypertension, benign prostatic hyperplasia, anxiety disorders, and other conditions. One of the main benefits of alpha-adrenergic antagonist therapy is that it can be used in combination with other medications, such as diuretics and ACE inhibitors, to achieve optimal blood pressure control. It is also well-tolerated by most patients and has a low incidence of side effects. However, like all medications, alpha-adrenergic antagonists do have potential side effects. These can include dizziness, fatigue, headaches, nausea, and priapism (a prolonged erection). Patients should be monitored closely for adverse effects, and should not discontinue use without consulting their healthcare provider. Overall, alpha-adrenergic antagonist therapy is an important tool in the management of hypertension and other cardiac conditions. It is a safe and effective treatment option for many patients and can help improve their quality of life while reducing their risk of serious cardiovascular events.

Research published in this journal

No peer-reviewed research on this exact topic has been published in Hypertension and Cardiology yet. Browse the journal →

Editorial oversight

Curated from peer-reviewed research published in Hypertension and Cardiology (ISSN 2329-9487).

Journal editorial board
Hatori Nobuo · Japan Gregor Leibundgut · Switzerland Yuejin Li · United States

This page summarises published research for orientation; it is not medical or professional advice.